Seeking Alpha
29 Jul 2026, 05:03 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
NeuroPace is seeking FDA approval via a PMA supplement to expand its device indication to include Idiopathic Generalized Epilepsy (IGE). — Expansion into a new patient population represents a significant increase in the total addressable market and potential revenue growth.
+0.60The company is currently discussing FDA feedback regarding the requirements for the PMA supplement submission. — Ongoing regulatory dialogue is a standard step in the approval process and indicates progress toward a formal filing.
+0.20Which stocks this story touches
The company is actively engaging with the FDA regarding an indication expansion, which is a typical progressive step for growth, though the outcome remains pending.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1h ago
